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Edmund J.S. Sonuga-Barke, PhD, on behalf of the European ADHD Guidelines Group (EAGG)Objective: We performed meta-analyses of randomized
controlled trials to examine the effects of neurofeedback
on attention-deﬁcit/hyperactivity disorder (ADHD)
symptoms and neuropsychological deﬁcits in children and
adolescents with ADHD.
Method: We searched PubMed, Ovid, Web of Science,
ERIC, and CINAHAL through August 30, 2015. Random-
effects models were employed. Studies were evaluated
with the Cochrane Risk of Bias tool.
Results: We included 13 trials (520 participants with
ADHD). Signiﬁcant effects were found on ADHD symp-
toms rated by assessors most proximal to the treatment
setting, that is, the least blinded outcome measure (stan-
dardized mean difference [SMD]: ADHD total
symptoms ¼ 0.35, 95% CI ¼ 0.110.59; inattention ¼ 0.36,
95% CI ¼ 0.090.63; hyperactivity/impulsivity ¼ 0.26,
95% CI ¼ 0.080.43). Effects were not signiﬁcant when
probably blinded ratings were the outcome or in trials
with active/sham controls. Results were similar whenSupplemental material cited in this article is available online.
www.jaacap.orgonly frequency band training trials, the most common
neurofeedback approach, were analyzed separately.
Effects on laboratory measures of inhibition (SMD ¼ 0.30,
95% CI ¼ 0.10 to 0.70) and attention (SMD ¼ 0.13, 95%
CI ¼ 0.09 to 0.36) were not signiﬁcant. Only 4 studies
directly assessed whether learning occurred after neuro-
feedback training. The risk of bias was unclear for many
Cochrane Risk of Bias domains in most studies.
Conclusion: Evidence from well-controlled trials with
probably blinded outcomes currently fails to support
neurofeedback as an effective treatment for ADHD.
Future efforts should focus on implementing standard
neurofeedback protocols, ensuring learning, and opti-
mizing clinically relevant transfer.
Key words: ADHD, neurofeedback, nonpharmacological
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J Am Acad Child Adolesc Psychiatry 2016;55(6):444–455.ttention-deﬁcit/hyperactivity disorder (ADHD) is a
common neurodevelopmental disorder characterizedA by age-inappropriate and impairing inattention and/
or hyperactivity/impulsivity.1,2 Among currently available
treatment options, psychostimulant and nonstimulant medi-
cations are efﬁcacious, at least in the short term, and widely
used.3 Nonpharmacological interventions—both dietary and
psychological—have also been extensively investigated.4-7
Among nonpharmacological approaches, neurofeedback has
been considered a promising ADHD treatment strategy since
the early 1970s.8-10 When applied to ADHD, neurofeedback is
intended to reduce ADHD symptoms by targeting aberrant
patterns of brain activity thought to underpin the condition.
Neurofeedback is implemented through the training of self-
regulation using operant reinforcement procedures; learning
of self-regulation is thus a keymechanism. To achieve this aim,electroencephalogram (EEG) indices of interest are converted
intovisual or acoustic signals and fedback automatically in real
time to the patient. For instance, cortical activity may be rep-
resented by the height or speed of a ball, plane, or cartoon
character presented using animation on a computer screen. In
this case, learning occurs when the object rises, falls, or ad-
vancesmore quickly in response to patients’ regulated changes
in brain activity. Two general neurofeedback approaches have
been used to treat ADHD: frequency band training (FBT) and
slow cortical potential training (SCP).When applied toADHD,
the former is intended to target alterations in cortical electrical
oscillations thought to be associated with ADHD, namely ele-
vationsof slow, relative to fast, brainwaveactivity, especially in
the frontal lobes (e.g., theta versus beta frequency11). The latter
aims to regulate cortical excitation thresholds by focusing on
activity generated by external cues (similar to event-related
potentials), focusing primarily on EEG components registered
in the late latency range, that is, several seconds after the cue.
For instance, this form of training has been used to target the
contingent negative variation (CNV) that occurs during this
timewindow and is involved in effective preparation, decisionJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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META-ANALYSIS OF NEUROFEEDBACK OUTCOMES IN ADHDmaking, and time estimation, which have all been found to be
deﬁcient in individualswithADHD, or at least in subgroups of
them.12,13
The efﬁcacy of nonpharmacological treatments for
ADHD, including neurofeedback, has been subject to a
number of earlier meta-analytic reviews.14-16 However, these
have sometimes been difﬁcult to interpret because of the
inclusion of studies with weak experimental designs (e.g., no
control arm, nonrandom allocation, or the use of nonblinded
measures), as discussed by Sonuga-Barke et al.17 On behalf of
the European ADHD Guidelines Group (EAGG), Sonuga-
Barke et al.17 attempted to address these limitations
through a meta-analysis of nonpharmacological in-
terventions that included only randomized controlled trials
(RCTs). It also addressed the issue of blinding by comparing
outcomes rated by individuals judged to be most proximal
to the therapeutic setting (often parents poorly blinded and
invested in the therapeutic outcome) and those provided by
reporters judged to be probably blinded. They found that the
effects of neurofeedback on ADHD total symptoms based on
most proximal ratings were highly signiﬁcant (standardized
mean difference [SMD] ¼ 0.59, 95% CI ¼ 0.31, 0.87). How-
ever, when only probably blinded measures were used, the
effects became nonsigniﬁcant (SMD ¼ 0.29; 95% CI ¼ 0.02
to 0.61). More recently, Micolaud-Franchi et al.18 followed a
similar approach, focusing their analyses on ADHD core
symptoms, but with a smaller set of studies (n ¼ 5) limited to
trials with particular control conditions. As in Sonuga-Barke
et al.,17 they found a signiﬁcant, positive effect of neuro-
feedback on ADHD core symptoms when considering most
proximal raters. Probably blinded scores were attenuated
and were signiﬁcant only for symptoms of inattention.
Applying the same meta-analyses protocol used in recent
EAGG reviews of behavioral interventions5 and cognitive
training,4 we here extend the focus of meta-analytic evidence
relating to neurofeedback for ADHD in a number of ways.
First, we included, among the outcomes, not only speciﬁc
ADHD behavioral dimensions (i.e., inattention and impul-
sivity/hyperactivity) but also ADHD-related neuropsycho-
logical deﬁcits such as inhibitory dysfunction. The latter may
be important, as they may take us closer to neural mediators
of the behavioral effects of neurofeedback.9 Second, we
addressed the relative efﬁcacy of different types of neuro-
feedback by restricting subanalyses to speciﬁc types of
treatment protocols, namely, FBT. Third, we examined the
impact of different aspects of trial design (e.g., use of a
sham/placebo design) or pragmatic “dosage” characteristics
of neurofeedback implementation (i.e., number of sessions).
Fourth, we addressed the crucial question of whether
neurofeedback-related learning at the neural level was
investigated and/or demonstrated in available trials.9 Fifth,
we examined whether the neurofeedback protocols used in
these studies could be considered “standard” in terms of the
criteria discussed by Arns et al.,19 which include elements
related to EEG bands/measures, electrode placement and
type, and feedback following learning. Finally, we applied,
for the ﬁrst time in a meta-analysis of neurofeedback for
ADHD, a rigorous assessment of study bias, namely, the
Cochrane Risk of Bias tool (RoB).20JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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The EAGG protocol was originally registered on the Inter-
national Prospective Register of Systematic Reviews (PROSPERO;
http://www.crd.york.ac.uk/PROSPERO, protocol number:
CRD42011001393). As in previous work,4,5 the original protocol was
adapted to take account of the broader scope of this systematic
review/meta-analysis. Most crucially, given that the scope of this
analysis included neuropsychological measures, the mandatory
requirement for studies to have ADHD symptoms-related outcomes
no longer applied (i.e., we included also studies presenting only
neuropsychological outcomes).Inclusion and Exclusion Criteria
To ensure high levels of methodological adequacy as recommended
by the Cochrane group and to avoid the inevitable bias caused by
dependence on investigators agreeing to provide data from unpub-
lished studies,20 only published studies were included. Only RCTs
using neurofeedback training were retained. Participants in the trials
were required to be between 3 and 18 years of age and to have a
diagnosis of ADHD (any subtype) or hyperkinetic disorder (HKD) or
to meet accepted cut-offs on validated ADHD symptom rating scales.
Trials that selected children with ADHD who had rare comorbid
disorders (e.g., Fragile X syndrome) were excluded. Control condi-
tions allowed were “treatment as usual,” “wait list,” “active,” or
“placebo/sham” (i.e., involving other forms of alternative training
regimen). As per the EAGG protocol, trials in which neurofeedback
was compared only with optimized medication or in which neuro-
feedbackwas added to optimizedmedicationwere excluded. Trials in
which medication was part of background normal clinical provision
in either the control or the active arm were included.Search Strategy
Details about the search strategy/syntax for each database are re-
ported in Supplement 1, available online. The ﬁnal search was
updated on August 30, 2015. Independent searches were conducted
by 2 authors (S.C. andM.F.), leading to the samenumber of references.Outcome Measures
To provide analytical robustness and in line with previous EAGG
meta-analyses,4,5,17,20 analyses of outcome domains were considered
reliable only if at least 5 RCTs were available. The planned outcomes
included the following: ADHD symptoms (total ADHD and inat-
tention and hyperactivity/impulsivity symptoms separately), neu-
ropsychological laboratory-based measures, measures of academic
functioning, and rating of severity of symptoms of comorbid con-
ditions (e.g., oppositional deﬁant disorder or anxiety disorders).Study Selection
Retrieved references were independently screened and blindly
double coded for eligibility by 2 authors (S.C. and M.F.). Any
disagreement was resolved by a senior author (E.S.-B.).Study Bias Assessment
Study quality was assessed independently by pairs of raters from
the authorship group using the Cochrane RoB tool.20 The RoB do-
mains included selection bias, performance bias, detection bias,
attrition bias, and other bias. Any disagreement was resolved
through consensus.www.jaacap.org 445
CORTESE et al.Data Extraction and Statistical Analysis
Trial information was entered into RevMan 5.3.21 Data extraction
was independently performed and cross-checked by the ﬁrst 2 au-
thors. SMD was calculated as mean pre- to posttreatment change in
the intervention group minus the mean pre- to posttreatment change
in the control group, divided by the pooled pretest standard devi-
ation with a bias adjustment.22 SMDs for each trial were combined
using the inverse variance method. Given the inherent heterogeneity
of studies, random effects models were used. The I2 statistic was
calculated to estimate between-trial SMD heterogeneity. When
multiple measurements were available for an outcome, the most
frequently reported outcome across trials or the outcome that was
judged to better tap the core of the construct was selected. To be
consistent with the EAGG protocol, we considered as probably
blinded those outcomes rated by an individual who was likely un-
aware of treatment allocation. Most proximal ratings were based on
assessors close to the therapeutic setting and often not blinded.
These ratings typically constituted a trial’s own primary outcome
measure and were therefore the assessment most available for
analysis.
Selection of most proximal and probably blinded ratings was
based on independent judgments and consensus of 3 authors
(S.C., M.F., and E. S.-B.). Where 2 or more probably blinded ratings
were available (which was sometimes the case on sham-controlled
trials), what was deemed the best probably blinded outcome
was selected for analysis, as in Cortese et al.4 When there were 2 or
more neuropsychological outcome measures, the one most
frequently reported across the relevant trials was selected. Four
sensitivity analyses were conducted. The ﬁrst included only trials
using an active or sham control. The second was restricted to
FBT trials. The third examined the effect of co-treatment with
medication and was restricted to studies with no/low levels of
medication (<30% of participants on medication, as per EAGG
protocol). The ﬁnal sensitivity analysis included only studies
meeting the criteria deﬁning a standard neurofeedback method-
ology as described by Arns et al.19 (see Supplement 2, available
online). Meta-regression was conducted to assess the effects of
number of training sessions. Publication bias was assessed with
funnel plots and Egger tests. Analyses were conducted using
RevMan 5.321 and STATA 13.1.23RESULTS
A total of 13 trials24-36 met entry criteria. Figure 1 presents
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) selection ﬂowchart. Table S1,
available online, provides a list of excluded papers with
reasons for exclusion. Retained studies included a total of
520 participants with ADHD. Table 1 gives information
about the characteristics of the retained trials. Table 2
summarizes results of all analyses. There were fewer than
5 studies available to examine some of the planned out-
comes such as working memory, parent ratings of execu-
tive functioning (e.g., Behaviour Rating Inventory of
Executive Function37), academic functioning (e.g., reading
or arithmetic ability), or comorbid conditions (e.g., ODD,
anxiety). Therefore, we did not perform analyses for such
outcomes.
When most proximal assessments were the outcome,
there was a small-to-moderate (SMD < 0.5) but signiﬁcant
effect on inattention, impulsivity/hyperactivity, and total
ADHD symptoms (Figure 2). In sensitivity analyses446 www.jaacap.orgconsidering only trials with an active/sham control, the ef-
fects dropped to nonstatistically signiﬁcant levels for total
ADHD and inattention symptoms. The effect was signiﬁcant
for hyperactivity/impulsivity but with a small effect size
(SMD ¼ 0.25), and the 95% CI was wide (CI ¼ 0.030.47).
When probably blinded outcomes were analyzed, effect
sizes for ADHD outcomes dropped further, and none were
signiﬁcant (Figure 3). Results were also not signiﬁcant when
considering only probably blinded measures from trials with
active/sham control (Table 2). When considering only trials
evaluating FBT, results were signiﬁcant for ADHD total
(SMD ¼ 0.37, 95% CI ¼ 0.090.64) and hyperactive/
impulsive symptoms (SMD ¼ 0.26, 95% CI ¼ 0.060.46)
from most proximal raters, but not for ADHD inattentive
symptoms or any ADHD symptoms rated by probably
blinded assessors. There were insufﬁcient trials (n ¼ 230,32)
for an analysis focused on SCP training (2 studies also used
both SCP and FBT31,33). When pooling only trials with no/
low medication, results were signiﬁcant only for ADHD
inattentive symptoms, most proximal (SMD ¼ 0.59, 95%
CI ¼ 0.310.88) and hyperactive/impulsive symptoms,
most proximal (SMD ¼ 0.32, 95% CI ¼ 0.060.58).
When the analysis was restricted to only the 7 trials that
met Arns et al.19 criteria for use of standard protocol, the
SMDs increased for most proximal outcomes, although the
95% CIs were wide (Table 2). There were only 3 trials27,30,31
that both used a standard protocol and had probably blin-
ded measures. In an exploratory analysis with these 3 trials,
the effect on total ADHD symptoms was signiﬁcant (SMD ¼
0.36), although the 95% CI was large (0.040.69).
The analysis of neuropsychological outcomes required
the pooling of diverse neuropsychological measures within
general domains (Table 1). Effects on laboratory measures of
inhibition (SMD ¼ 0.30, 95% CI ¼ 0.10 to 0.70) and
attention (SMD ¼ 0.13, 95% CI ¼ 0.09 to 0.36) were not
signiﬁcant.
Direct evidence that neurofeedback training led to
learning was gathered in only 4 trials27,29,33,36 and was
positive for only 1 trial.27 In 1 study,29 there was a partial
learning effect. In Heinrich et al.,32 there was indirect evi-
dence of learning: the increase in the contingent negative
variation (a slow cortical potential) suggests that children
learned what was trained.
Studies varied considerably in terms of risk of bias
(Figures S1 and S2, available online). For approximately half
of the RoB domains across studies, the level of risk was
unclear. For those categories that could be determined, 8
trials were rated as having a high risk of bias in at least 1
domain. In general, the major concern (i.e., high risk of bias)
related to blinding of participants, personnel, and assessors.
Among “other bias,” funding was not clearly stated in a
sizable portion of studies.
Funnel plots and Egger test results (Figures S3 and S4,
available online) suggested little evidence of publication
bias, although the number of trials was insufﬁcient to
establish a reliable estimate. Finally, meta-regression ana-
lyses did not support a relationship between the number of
training sessions and most proximal or probably blinded
outcomes (Figures S5 and S6, available online).JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of selection of studies (last
search updated on August 30, 2015). Note: Reasons for exclusion of each article are reported in Table S1. aFour articles included in
the search results (29,35,36,46) refer to the same sample as refered to by another four articles (44,43,45,31, respectively), so the PRISMA
flowchart does not count them twice.
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META-ANALYSIS OF NEUROFEEDBACK OUTCOMES IN ADHDDISCUSSION
The rationale for the use of neurofeedback for ADHD rests
on the idea that promoting normalization or self-regulation
of brain activity will translate into improved cognitive and
behavioral control that is deﬁcient in individuals with
ADHD. A previous meta-analysis17 based on a limited
number of trials (n ¼ 8) was inconclusive with regard to the
efﬁcacy of neurofeedback for ADHD symptoms. Although
there were moderate but highly signiﬁcant effects (SMD ¼
0.59; 95% CI ¼ 0.310.87) for ADHD outcomes rated by
most proximal assessors, these were not signiﬁcant when
only probably blinded outcomes were considered (SMD ¼
0.29; 95% CI ¼ 0.02 to 0.61). The current meta-analysis,
including an additional 5 RCTs, provides what is likely to
be a more reliable estimate of the effects of neurofeedback
for ADHD. Importantly, the additional statistical power also
allowed us to explore the impact of neurofeedback type, the
effect of type of control, the impact of number of neuro-
feedback sessions, and the value of using standardJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 6 JUNE 2016neurofeedback procedures. Although it does not provide a
deﬁnitive statement as to the value of neurofeedback, the
current analysis has clariﬁed a number of issues.
In general, the effect size estimates in the current analysis
are substantially smaller compared to the previous one by
Sonuga-Barke et al.17 This is due to the smaller effect sizes
reported in the most recent trials not included in Sonuga-
Barke et al.17 For instance, SMDs dropped for most prox-
imal and probably blinded total ADHD outcomes by 41%
and 49%, respectively, although the analysis based on most
proximal ratings of ADHD core symptoms remained sig-
niﬁcant. Crucially, as in the previous meta-analysis,17 when
the risk of biased effect size estimates was reduced either by
selecting probably blinded outcomes or by limiting analysis
to trials with a high-quality control arm (sham or active),
effects were no longer signiﬁcant. Importantly, and in
contrast to previous meta-analyses,15,18 there was no evi-
dence for a particular beneﬁt with regard to inattention
symptoms, which have previously been hypothesized to bewww.jaacap.org 447
TABLE 1 Characteristics of Studies Included in Meta-Analysis
Triala
Design Training Sample Outcomes
Control Type NF
Standard
Protocolb
Sessions,
n
Follow-
Up (mo)
Nc
t
c
Meds (%)
t
c Age (mo)
ADHD Symptoms Neuropsychological Outcomes
M-PROX P-BLIND Inhibitory Control Attention
Arnold26 Sham
placebod
FTBe no 40 2 25
11
0
0
72-144 Parent Teacher BRC
Bakhshayesh27 EMG
biofeedback
FTB yes 30 6f 18
17
22
18
72-168 Parent Teacher CPT (commission) CPT (omission)
Beauregard28 No treatment FTBg yes 40 N/S 15
5
0
0
96-144 Parent Counting Stroop
(interference)
CPT (integrated
visual and
auditory)
Bink29 TAU FTBh no 37 12 45
26
44.4
61.5
23i,j
193.2  39.6 (T)
194.4  40.8 (C)
Parent Color Stroop
(Interference)
D2 attention (total
correct)
Christiansen30 Self-manag. SCP yes 30 12 58 (tot.) 101.04  16.08 Parent Teacher
Gevensleben31 AT SCP þ FTBk yes 36 6 59
35
8.5
2.9
118  15 (T)
112  14 (C)
Parent Teacher ANT, Orienting
(data from46, that
refers to the same
sample of31)
ANT,
Conﬂict
(data from46,
that refers to the
same
sample of31)
Heinrich32 WL SCPl yes 25 N/S 13
9
46.1
44.4
90-165 Parent CPT (commission) CPT (omission)
Holtmann25 ATm FTBl yes 20 N/S 20
14
79.4n 123.6 
14.4 (mean)
Parent Stop Signal Task
Linden24 WL FTB yes 40 N/S 8
6
0
0
110 (mean) Parent
Maurizio33 EMG
biofeedback
SCP þ FTBo no 36 N/S 13
12
7.6i
8.3i
102-154.8 Parent Teacher D2 attention
(total score)
Steiner34p ATm, WLq FTBh no 23 N/S 9
11
60 148.8  10.8 Parent Teacher
Steiner35 CT, WLq FTBh no 40 6r 34
36
44.1
55.5
100.8  13.2 (T)
100.8 
13.2 (C)
Parent BOSS
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TABLE 1 Continued
Triala
Design Training Sample Outcomes
Control Type NF
Standard
Protocolb
Sessions,
n
Follow-
Up (mo)
Nc
t
c
Meds (%)
t
c Age (mo)
ADHD Symptoms Neuropsychological Outcomes
M-PROX P-BLIND Inhibitory Control Attention
VanDongen45
Vollebregt36s
Placebo NF FTBt no 30 6u 22
19
54.5
73.7
126.0  26.4 (T)
128.4 
27.6 (C)
Investigator Teacher
Note: Studies are listed in alphabetical order. ADHD ¼ attention-deficit/hyperactivity disorder; ANT ¼ Attention Network Test; AT ¼ attention training; BOSS ¼ Behavioral Observation of Students in Schools; BRC ¼ brain
resource center computer-based normed neuropsychological test; C ¼ control group; CPT ¼ continuous performance test; CT ¼ cognitive training; EMG ¼ electromyography; FTB ¼ frequency theta/beta; NF ¼
neurofeedback; N/S ¼ not specified; SCP ¼ slow cortical potential; SMR ¼ sensory motor rhythm; SST ¼ Stop Signal Test; T ¼ treatment condition; TAU ¼ treatment as usual; WL ¼ waiting list.
aIn alphabetical order, followed by study reference number.
bStandard methodology described elsewhere.19
cN is the number of individuals in the treatment (T) and control (C) conditions.
dEqual intensity and duration.
eEEG recorded from an electrode placed at position Cz vs. the ears as reference
fResults of the follow-up were not published in this article.
gSMRþbeta.
hSMR.
iChildren were off medication 48 hours prior to all the assessments.
jNumber in each group not specified.
kSMRþbeta Cz-ears.
lCalculated from Cz vs mastoids.
mStandard computer format.
nA total of n¼27 were medicated (no indication of how many in each group).
oB¼beta, LORETA Tomography.
pWe used parent #1 because parent #2 measures were available for a smaller sample (n ¼ 9 for parent #1 and n ¼ 5 for parent #2 in NF and n ¼ 11 for parent #1 and n ¼ 9 for parent #2 in the waiting list group);
a discussion of the outcomes selected from this study is available elsewhere.47,48
qThe WL arm was used as comparator in the analyses.
rThe results of the follow-up phase are published elsewhere.43
sThese 2 articles refer to the same study and present analyses on different outcomes.
tIndividualized, mainly T/B, B ¼ SMR.
uData reported only at endpoint (15 wk).
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TABLE 2 Summary of Results
Outcome Trials Included Measure Trials, n
Effect of Intervention Heterogeneity
SMD 95% CI p I2 p
ADHD
symptoms
Total All MPROX 13 0.35 0.11, 0.59 .004 41 .06
PBLIND 8 0.15 0.08, 0.38 .20 0 .74
Active/sham MPROX 7 0.22 0.08, 0.52 .14 35 .16
PBLIND 6 0.20 0.05, 0.45 .12 0 .66
FBT MPROX 9 0.37 0.09, 0.64 .01 36 .13
PBLIND 5 0.03 0.29, 0.35 .84 0 .76
Low medication MPROX 7 0.39 0.01, 0.79 .05 48 .08
PBLIND 5 0.26 0.01, 0.54 .06 0 .76
Standard protocol MPROX 7 0.45 0.02, 0.88 .04 53 .05
Inattention All MPROX 11 0.36 0.09, 0.63 .009 43 .07
PBLIND 7 0.06 0.24, 0.36 .70 41 .12
Active/sham MPROX 6 0.26 0.10, 0.63 .16 49 .08
PBLIND 5 0.21 0.09, 0.50 .17 16 .31
FBT MPROX 9 0.33 0.00, 0.67 .05 51 .04
PBLIND 5 0.04 0.37, 0.28 .79 19 .29
Low medication MPROX 6 0.59 0.31, 0.88 .0001 0 .63
Standard protocol MPROX 5 0.55 0.01, 1.09 .05 58 .05
Hyper/imp All MPROX 10 0.26 0.08, 0.43 .004 0 .80
PBLIND 7 0.17 0.05, 0.39 .13 0 .59
Active/sham MPROX 6 0.25 0.03, 0.47 .03 0 .92
PBLIND 5 0.15 0.11, 0.41 .26 0 .80
FBT MPROX 8 0.26 0.06, 0.46 .01 0 .62
PBLIND 5 0.15 0.15, 0.44 .33 6 .37
Low medication MPROX 5 0.32 0.06, 0.58 .02 0 .44
Neuropsychological
test performance
Attention All Objective 8 0.13 0.09, 0.36 .26 0 .72
FBT Objective 5 0.11 0.16, 0.38 .43 0 .76
Inhibition All Objective 6 0.30 0.10, 0.70 .15 56 .05
Note: Pooled standardized mean differences (SMD) are shown for each outcome. Positive SMDs indicate that neurofeedback is more efficacious than control condition.
Significant effects are indicated in boldface type. There were insufficient (n < 5) trials for the following: standard neurofeedback (NF), probably blinded rater (PBLIND)
total (tot; n ¼ 3), PBLIND inattention (In; n ¼ 3); standard protocol, most proximal rater (MPROX), hyperactivity/impulsivity (hyp/imp; n ¼ 4), and PBLIND (tot, In,
hyper/imp) (n ¼ 3); trials using a version of frequency band training including thetaebeta ratio training (FBT), inhibition (n ¼ 4 trials); low medication, inattention,
PBLIND (n ¼ 4) and hyp/imp, PBLIND (n ¼ 4). Active/sham ¼ only trials with an active/sham control arm; ADHD ¼ attention-deficit/hyperactivity disorder; All ¼ all
trials meeting inclusion criteria with available measures; SMT ¼ self-management therapy; TAU ¼ treatment as usual.
CORTESE et al.more amenable to neurofeedback. This was also reﬂected in
our failure to ﬁnd effects on laboratory measures of attention
such as the continuous performance test.
Previously, Sonuga-Barke et al.17 have argued that the
substantial drop in SMDs between most proximal and
probably blinded analyses is likely to be the result of biases
in perception in favor of the active treatment when one relies
on observations by raters aware of treatment allocation.
However, there are some other explanations. For instance, it
is possible that probably blinded ratings are, for some
reason, less sensitive to change than most proximal mea-
sures, perhaps either because of the instruments used or the
person rating. Teachers, for instance, may be less sensitive to
change than parents. However, essentially the same ques-
tionnaires were completed by both of these types of raters. It
is also possible that proximal ratings accurately reﬂected real450 www.jaacap.orgimprovements in the setting in which the treatment was
delivered, but these effects failed to generalize to more distal
settings in which blinded measures were recorded. This
explanation seems unlikely, as probably blinded measures
were also collected in the treatment setting for some trials,
and these followed the same pattern. The type of neuro-
feedback protocol implemented in the trials did not seem to
be an important factor in determining the results. When we
restricted the analysis to trials using some form of FBT such
as that focusing on alteration of the ratio between slow theta
and faster beta oscillations, there was no increase in the
effects of treatment. There was an insufﬁcient number of
trials (n ¼ 2)30,32 using SCP training exclusively to state
any ﬁrm assertion about this approach. The results
raise the question of whether current training protocols
have the appropriate treatment target. For instance, theJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 6 JUNE 2016
FIGURE 2 Forest plots for meta-analysis of effects on attention-deficit/hyperactivity disorder (ADHD) core symptoms assessed
by most proximal (MPROX) raters. Note: A) ADHD total symptoms; B) inattentive symptoms; C) hyperactive/impulsive symptoms.
SE ¼ standard error; Std ¼ standardized.
META-ANALYSIS OF NEUROFEEDBACK OUTCOMES IN ADHDdevelopmental stability of EEG frequency band alterations
in ADHD from childhood into adulthood has been ques-
tioned,11,38,39 although the most commonly observed ADHD
effects with regard to evoked brain responses relate to early
rather than later components not targeted in current neu-
rofeedback protocols. Therefore, the rationale for theta–beta
feedback has been very critically discussed.9,40
The value of a treatment meta-analysis is, of course,
constrained by the methodology of the trials that it includes.
It is therefore possible that the results of our meta-analysis
reﬂect the methodological weaknesses of the includedJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 6 JUNE 2016studies rather than the weakness of neurofeedback as such.
Indeed, the current set of 13 trials, taken as a whole, had a
number of methodological short-comings. First, only 4
studies tested,27,29,33,36 and then only 1 study,27 reported
directly and positively whether neurofeedback training had
actually led to learning as indexed by changes/improve-
ment at the electrophysiological level. In the 1 positive
trial,27 the mediating role of changes in the electrophysio-
logical signature leading to changes at the symptom level
was not investigated. This is a crucial point, because if
neurofeedback cannot bring about the expected changes atwww.jaacap.org 451
FIGURE 3 Forest plots for meta-analysis of effects on attention-deficit/hyperactivity disorder (ADHD) core symptoms assessed by
probably blinded (PBLIND) raters. Note: A) ADHD total symptoms; B) inattentive symptoms; C) hyperactive/impulsive symptoms.
SE ¼ standard error; Std ¼ standardized.
CORTESE et al.the neural level, then treatment effects are more likely to be
artifacts of some other, nonspeciﬁc aspect of the training.
Such a situation may be similar to cognitive training tar-
geting but not improving working memory, or to a drug
with an established neurotransmitter proﬁle not reaching the
corresponding neural target system in the patient’s brain. On
the other hand, tests for learning of neural self-regulation,
and addressing relations between learning and clinical
improvement, would also need to consider more complex
models and alternative mechanisms, for example allowing
for initial, delayed, and nonlinear types of learning and
translation,41 before concluding that effects are nonspeciﬁc.
Further research should address whether possible neuronal
modiﬁcations underpin putative behavioral changes in
ADHD symptoms following neurofeedback.
A number of groups have deﬁned what constitutes a
standard neurofeedback protocol in terms of the number of
training sessions, the reinforcement parameters operating,
the EEG montage, etc. (see Vernon et al.42 for a justiﬁcation).452 www.jaacap.orgInterestingly, only 54% of the studies in the current analysis
met such a threshold. When we restricted the analysis to that
subset of trials, our results were somewhat mixed; the effect
size for total ADHD and inattention increased by about 20%.
However, for all most proximal outcomes, 95% CIs were
wide and close to nonsigniﬁcance. Unfortunately, there were
only 3 studies with a standard protocol including probably
blinded ratings,27,30,31 so that ﬁrm conclusions on the value
of standardized protocols as deﬁned by Arns et al.19 cannot
be drawn. In addition, the level of methodological rigor
speciﬁcally related to RCT conduct, as explored by the RoB
tool, was in general unclear. The level of blinding was un-
clear or insufﬁcient in many studies. In addition, 1 particu-
larly striking omission in the majority of trials was the report
of possible potential conﬂicts of interest. This would seem to
be a major oversight in the current literature, given the
growing presence of neurofeedback training companies in
the commercial treatment marketplace. Given these limita-
tions, it seems that without evidence for the learning of self-JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 6 JUNE 2016
META-ANALYSIS OF NEUROFEEDBACK OUTCOMES IN ADHDregulation, and given the widespread use of nonstandard
neurofeedback protocols, it is difﬁcult to draw deﬁnitive
conclusions about the ultimate value of neurofeedback
approaches.
The EAGG has also recently completed meta-analyses
for behavioral interventions and cognitive training using
the same core protocol as used here.4,5 There are striking
similarities but also some differences between the results of
the present meta-analysis and those from these recent
EAGG meta-analyses. In terms of effects on ADHD symp-
toms, neurofeedback, cognitive training, and behavioral
interventions show almost identically sized positive and
statically signiﬁcant effects on total ADHD symptoms scores
rated by most proximal assessors (SMD: behavioral
interventions, 0.35; cognitive training, 0.37; neurofeedback,
0.35). Furthermore, in all 3 cases, the effects drop substantially
to nonsigniﬁcant levels when probably blinded outcomes are
used. This is more evident for behavioral interventions where
the effects drop to 0 but is also substantial for neurofeedback
and cognitive training (SMD ¼ 0.15 and 0.20, respectively).
However, 1 quite striking difference among the 3 meta-
analyses is that both behavioral interventions and cognitive
training had predictable positive effects on outcomes other
than ADHD. For instance, for working memory training,
there were highly signiﬁcant effects on neuropsychological
measures of working memory, whereas behavioural in-
terventions improved parenting rated by independent ob-
servers and had positive effects on probably blinded
measures of conduct problems. By contrast, we did not ﬁnd
evidence for effects of neurofeedback on neuropsychological
outcomes.
Caution is required when interpreting these ﬁndings,
given a number of limitations in addition to the issues
raised with regard to the nature of the trials above. First,
effect size estimates may be inﬂated because of the fail-
ure to report intention to treatment analyses in most
trials. Second, there were insufﬁcient trials measuring
important outcomes such as working memory task per-
formance, academic skills, general functional impairment,
IQ, and other mental health problems such as conduct
problems. Third, few trials included long-term outcomes
(Table 1) to allow an evaluation of the extent to which
effects on clinical symptoms grew over time or effects on
neuropsychological processes persisted. Fourth, no trial
recruited participants based on the presence of ADHD-
related deﬁcits in EEG signature (i.e., altered theta–beta
ratio). This may limit the chance for neurofeedback-
related improvements in symptoms. Fifth, it was neces-
sary to pool data from diverse measures from different
tasks to have sufﬁcient trials to analyze neuropsycho-
logical functions. Although in principle the pooled
measures tapped the same neuropsychological domain,
this inevitably was a somewhat arbitrary process that
likely increased SMD heterogeneity. In addition, ADHD
is a pathophysiologically heterogeneous disorder, and
distinct EEG subtypes have been described (e.g., cortical
hyperarousal versus hypoarousal subtypes). Patients
might require more speciﬁc and tailored training target-
ing different deﬁcits associated with ADHD. CombiningJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 6 JUNE 2016different neuroimaging approaches with neurofeedback
training might be a useful approach in the future.
Finally, the range of number of sessions across studies
may have been too restricted to allow the detection of
possible effect of session number.
In summary, the current meta-analysis shows that evi-
dence from well-controlled trials with probably blinded
outcomes does not support neurofeedback as an effective
treatment for ADHD, in terms of either ADHD symptoms or
other cognitive correlates. Future research should focus on
the following: identifying the most appropriate electro-
physiological treatment target; increasing the use of stan-
dard EEG and learning protocols; developing new methods
to optimize the chances that neurofeedback leads to learning
at the brain level; and identifying predictors of treatment
response for individual patients or at least in distinctive
subgroups of children. &Accepted March 28, 2016.
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